- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05791110
PE-1 in the Diagnosis of Pancreatic Exocrine Insufficiency
Diagnostic Value of Fecal Pancreatic Elastase 1 in the Diagnosis of Pancreatic Exocrine Insufficiency: a Multi-center Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fecal Pancreatic Elastase 1 (PE-1)Test has high diagnostic accuracy in pancreatic exocrine insufficiency (PEI), has become a painless noninvasive diagnostic modality in clinical practice, and has been widely used in clinical practice.
However, in China, the diagnostic ability of the PE-1 test in the Chinese population has not been demonstrated and has not been reported. Meanwhile, pancreatin stimulation, 13C-mixed triglyceride breath test, and N-benzoyl-L-tyrosyl-p-aminobenzoic acid test required drugs, which cannot pass the examination of the drug administration and were not allowed to be carried out to diagnose PEI in China. In addition pancreatin stimulation is an invasive test has certain risks for subjects and 72-hour fecal fat quantification was mainly used for the diagnosis of severe PEI. Therefore, This study adopted strict clinical diagnosis as a comparative method for PE-1 test to judge the ability of PE-1 test to diagnose PEI in the Chinese population.
This study aims to clarify the application efficacy of PE-1 test in PEI through a multi-center, prospective clinical study comparing PE-1 test with strict clinical diagnosis. To study the accuracy of PE-1 test in the diagnosis of PEI.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Changhai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 【patients with clinical diagnosed PEI】
- Inpatients or outpatients of both sexes, aged 18 to 80 years.
Patients with pancreatic disease or after pancreatic or gastric resection (one of the following)
- Chronic pancreatitis.
- At least 3 months after pancreatectomy (surgical procedures included total pancreatectomy, pancreaticoduodenectomy, pylorus-preserving pancreaticoduodenectomy, and distal pancreatectomy).
- Patients recovering from severe acute pancreatitis (duration less than 24 months).
- More than 3 months after gastrectomy (surgical methods included total gastrectomy, proximal gastrectomy, and distal gastrectomy).
Enrolled patients had at least one of the following symptoms (except those after pancreatectomy)
- abdominal distension.
- Weight loss (weight loss is defined as loss of more than 5% of basal body weight in one year).
- steatorrhea.
- Agreed to participate in the study and signed an informed consent form.
【patients without clinical diagnosed PEI】
- Both male and female, aged between 18 and 80 years old.
Patients who met one of the following criteria were included in the study:
- Patients with functional gastrointestinal diseases who had no history of pancreatectomy, gastrectomy, or abdominal radiotherapy were included.
- Healthy volunteers.
- Patients with benign hepatobiliary diseases, thyroid, breast diseases, and digestive tract diseases who had no history of pancreatectomy, gastrectomy, or abdominal radiotherapy were included.
- Agreed to participate in the study and signed an informed consent form.
Exclusion Criteria:
- Pregnant women
- Critically ill patients
- The subjects with mental disorders were unable to cooperate with the researchers
- patients who had undergone ileocolon bladder replacement surgery or complicated with intestinal obstruction and other diseases that could not collect feces
- the quantity of fecal samples, storage and transportation conditions of samples do not meet the requirements of the kit
- patients who underwent two or more times of gastrectomy or pancreatectomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Pancreatic exocrine function
Strict clinical diagnosis and fecal pancreatic elastase 1 test were performed for each subject (including PEI patients (n=525) and non-PEI patients (n=528))
|
Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reliability of fecal pancreatic elastase 1 test in the diagnosis of PEI
Time Frame: 1 week
|
Diagnostic consistency (kappa value) of fecal pancreatic elastase 1 test
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of fecal pancreatic elastase 1 test in the diagnosis of PEI
Time Frame: 1 week
|
Diagnostic sensitivity, specificity, positive likelihood ratio, negative likelihood ratio of fecal pancreatic elastase 1 test
|
1 week
|
Predictive value of fecal pancreatic elastase 1 test in the diagnosis of PEI
Time Frame: 1 week
|
Positive predictive value, negative predictive value of fecal pancreatic elastase 1 test
|
1 week
|
Accuracy, reliability, and predictive of fecal pancreatic elastase 1 test in the diagnosis of severe PEI
Time Frame: 1 week
|
Severe PEI was defined as PE-1 content in feces less than 100μg/g.
Diagnostic consistency (kappa value), sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value, negative predictive value of fecal pancreatic elastase 1 test in severe PEI.
|
1 week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PE1-PEI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Exocrine Insufficiency
-
AbbottCompletedPancreatic Exocrine Insufficiency, Chronic Pancreatitis, PancreatectomyJapan
-
Solvay PharmaceuticalsTerminatedPancreatic Exocrine Insufficiency Due to Chronic PancreatitisCzech Republic, Denmark, Hungary, Latvia, Poland, Russian Federation, Sweden
-
Abbott ProductsDatamapCompletedPancreatic InsufficiencyIndia
-
Ohio State UniversityAbbVieActive, not recruiting
-
Ruijin HospitalRecruitingPancreatic Exocrine Insufficiency | Pancreaticoduodenectomy | Pancreatic Enzyme Replacement TherapyChina
-
Federal Research and Clinical Center of Physical-Chemical...Moscow State University of Medicine and DentistryCompletedChronic Pancreatitis | Pancreatic Exocrine InsufficiencyRussian Federation
-
Solvay PharmaceuticalsCompletedChronic Pancreatitis | Pancreatic Exocrine Insufficiency | PancreatectomyUnited States, Bulgaria, Poland, Puerto Rico, Russian Federation, Serbia, South Africa, Ukraine
-
Assiut UniversityNot yet recruitingPancreatic Exocrine Insufficiency
-
Azidus BrasilUnknown
-
AbbottCompletedExocrine Pancreatic Insufficiency, Chronic PancreatitisJapan
Clinical Trials on Fecal pancreatic elastase 1 test
-
Changhai HospitalRuijin Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School...RecruitingDiabetes Mellitus | Chronic Pancreatitis | Pancreatic Exocrine Insufficiency | Community Populations | Fecal Elastase-1 TestChina
-
Hospital Clinico Universitario de SantiagoRecruitingDiabetes Mellitus, Type 2Spain
-
Corporacion Parc TauliCompletedExocrine Pancreatic InsufficiencySpain
-
Assiut UniversityNot yet recruitingPancreatic Exocrine Insufficiency
-
Rush University Medical CenterRecruitingWeight Gain | Exocrine Pancreatic InsufficiencyUnited States
-
Qilu Hospital of Shandong UniversityLanZhou University; First Affiliated Hospital, Sun Yat-Sen University; Wuhan... and other collaboratorsRecruitingPancreatic Neoplasms | Pancreatic Diseases | Pancreatitis | Pancreatic Ductal Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Elastase 1China
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
University Hospital, BrestRegistre des Tumeurs Digestives du Finistère; Centre Régional de Coordination...CompletedFemale | Colonoscopy | Occult Blood | Mass Screening | Early Detection of Cancer | Colorectal Neoplasms Malignant | Middle AgedFrance
-
Mahidol UniversityCompletedColorectal Cancer | Colitis | Colorectal AdenomaThailand
-
ClearNote HealthNot yet recruitingPancreatic CancerUnited States